Comparative Measurements of Hypoxia in Human Brain Tumors Using Needle Electrodes and EF5 Binding

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1886-1892

  Evans, Sydney M ^a,e   Judy, Kevin D ^a   Dunphy, Isolde ^a   Jenkins, W Timothy ^a   Nelson, Peter T ^a   Collins, Ruth ^a   Wileyto, E Paul ^a   Jenkins, Kevin ^a   Hahn, Stephen M ^a   Stevens, Craig W ^c   Judkins, Alexander R ^a   Phillips, Peter ^b   Geoerger, Birgit ^d   Koch, Cameron J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2-(2-NITRO-1H-IMIDAZOL-1-YL)-N-(2,2,3,3,3-PENTAFLUOROPROPYL)ACETAMIDE; DRUG DERIVATIVE; ETANIDAZOLE; FLUORINATED HYDROCARBON; OXYGEN;

ADULT; ARTICLE; BRAIN TUMOR; CALIBRATION; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRODE; ENDOTHELIUM; GLIA CELL; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEASUREMENT; MITOSIS; OXYGEN CONCENTRATION; OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; AGED; CELL HYPOXIA; METABOLISM; MIDDLE AGED; NEEDLE;

ADULT; AGED; BRAIN NEOPLASMS; CELL HYPOXIA; ELECTRODES; ETANIDAZOLE; HUMANS; HYDROCARBONS, FLUORINATED; MIDDLE AGED; NEEDLES; OXYGEN;

EID: 12144290194     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2424     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts and Figures, 2002. Atlanta, GA: Surveillance Research, 2002.
2. CBTRUS Statistical Report: Primary Brain Tumors in the United States, 1995-1999, p. 45. Chicago: Central Brain Tumor Registry of the Unites States, 2002.
3. Collingridge, D. R., Piepmeier, J. M., Rockwell, S., and Knisely, J. P. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother. Oncol., 53: 127-131, 1999.
4. 2 distribution in human malignant brain tumours. Adv. Exp. Med. Biol., 345: 465-470, 1994.
5. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys., 29: 427-431, 1994.
6. Kleihues, P., and Sobin, L. H. World Health Organization classification of tumors. Cancer (Phila.), 88: 2887, 2000.
7. Kohshi, K., Kinoshita, Y., Imada, H., Kunugita, N., Abe, H., Terashima, H., Tokui, N., and Uemura, S. Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br. J. Cancer, 80: 236-241, 1999.
8. Ogawa, K., Yoshii, Y., Inoue, O., Toita, T., Saito, A., Kakinohana, Y., Adachi, G., Ishikawa, Y., Kin, S., and Murayama, S. Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high grade gliomas. Radiother. Oncol., 67: 63-68, 2003.
9. Kleinberg, L., Grossman, S. A., Carson, K., Lesser, G., O'Neill, A., Pearlman, J., Phillips, P., Herman, T., and Gerber, M. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a Phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J. Clin. Oncol., 20: 3149-3155, 2002.
10. Del Rowe, J., Scott, C., Werner-Wasik, M., Bahary, J. P., Curran, W. J., Urtasun, R. C., and Fisher, B. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol., 18: 1254-1259, 2000.
11. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289, 1997.
12. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
13. Kaanders, J. H., Wijffels, K. I., Marres, H. A., Ljungkvist, A. S., Pop, L. A., van den Hoogen, F. J., de Wilde, P. C., Bussink, J., Raleigh, J. A., and van der Kogel, A. J. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res., 62: 7066-7074, 2002.
14. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
15. Nordsmark, M., Alsner, J., Keller, J., Nielsen, O. S., Jensen, O. M., Horsman, M. R., and Overgaard, J. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer, 84: 1070-1075, 2001.
16. Lindegaard, J. C., Overgaard, J., Bentzen, S. M., and Pedersen, D. Is there a radiobiologic basis for improving the treatment of advanced stage cervical cancer? J. Natl. Cancer Inst. Monogr., 21: 105-112, 1996.
17. Stone, H. B., Brown, J. M., Phillips, T. L., and Sutherland, R. M. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat. Res., 136: 422-434, 1993.
18. Evans, S. M., Hahn, S., Pook, D. R., Jenkins, W. T., Chalian, A. A., Zhang, P., Stevens, C., Weber, R., Weinstein, G., Benjamin, I., Mirza, N., Morgan, M., Rubin, S., McKenna, W. G., Lord, E. M., and Koch, C. J. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res., 60: 2018-2024, 2000.
19. Evans, S. M., Hahn, S. M., Magarelli, D. P., Zhang, P. J., Jenkins, W. T., Fraker, D. L., Hsi, R. A., McKenna, W. G., and Koch, C. J. Hypoxia in human intraperitoneal and extremity sarcomas. Int. J. Radiat. Oncol. Biol. Phys., 49: 587-596, 2001.
20. Evans, S. M., Hahn, S. M., Magarelli, D. P., and Koch, C. J. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am. J. Clin. Oncol., 24: 467-472, 2001.
21. Koch, C. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimidazole EF5. In: S. A. Packer (ed.), Antioxidants and Redox Signaling. San Diego, CA: Academic Press, 2001.
22. Evans, S. M., Joiner, B., Jenkins, W. T., Laughlin, K. M., Lord, E. M., and Koch, C. J. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazo1-1-yl).N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br. J. Cancer, 72: 875-882, 1995.
23. Evans, S. M., Jenkins, W. T., Joiner, B., Lord, E. M., and Koch, C. J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res., 56: 405-411, 1996.
24. Koch, C. J., Evans, S. M., and Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity. Br. J. Cancer, 72: 869-874, 1995.
25. Fenton, B. M., Lord, E. M., and Paoni, S. F. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation. Radiat. Res., 153: 75-83, 2000.
26. Lee, J. Siemann, D. W., Koch, C. J., and Lord, E. M. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int. J. Cancer, 67: 372-378, 1996.
27. Woods, M. L., Koch, C. J., and Lord, E. M. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies. Int. J. Radiat. Oncol. Biol. Phys., 34: 93-101, 1996.
28. Koch, C. J., Hahn, S. M., Rockwell, K., Jr., Covey, J. M., McKenna, W. G., and Evans, S. M. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother. Pharmacol., 48: 177-187, 2001.
29. Evans, S., and Koch, C. Prognostic significance of hypoxia in human tumors. Cancer Lett., 195: 1-16, 2003.
30. Jenkins, W. T., Evans, S. M., and Koch, C. J. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int. J. Radiat. Oncol. Biol. Phys., 46: 1005-1017, 2000.
31. Curran, W. J., Jr., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., and Krisch, R. E. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst., 85: 704-710, 1993.
32. Kajino, H., Chen, Y. Q., Chemtob, S., Waleh, N., Koch, C. J., and Clyman, R. I. Tissue hypoxia inhibits prostaglandin and nitric oxide production and prevents ductus arteriosus reopening. Am. J. Physiol., 279: R278-R286, 2000.
33. Kajino, H., Chen, Y. Q., Seidner, S. R., Waleh, N., Mauray, F., Roman, C., Chemtob, S., Koch, C. J., and Clyman, R. I. Factors that increase the contractile tone of the ductus arteriosus also regulate its anatomic remodeling. Am. J. Physiol., 281: R291-R301, 2001.
34. Bialik, S., Geenen, D. L., Sasson, I. E., Cheng, R., Horner, J. W., Evans, S. M., Lord, E. M., Koch, C. J., and Kitsis, R. N. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J. Clin. Investig, 100: 1363-1372, 1997.
35. Wouters, B. G., and Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiation therapy. Radiat. Res., 147: 541-550, 1997.
36. m for radiosensitization of human tumor cells by oxygen is much greater than 3 mmHg and is further increased by elevated levels of cysteine. Radiat. Res., 156: 388-398, 2001.
37. Lal, A., Peters, H., St Croix, B., Haroon, Z. A., Dewhirst, M. W., Strausberg, R. L., Kaanders, J. H., van der Kogel, A. J., and Riggins, G. J. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst., 93: 1337-1343, 2001.
38. Pietsch, T. Expression and distribution of VEGF protein in human brain tumors. Acta Neuropathol., 93: 109-117, 1997.
39. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.), 359: 845-848, 1992.
40. Ziemer, L., Koch, C., Maity, A., Magarelli, D., Horan, A., and Evans, S. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia, 6: 500-508, 2001.
41. Nishioka, T., Oda, Y., Seino, Y., Yamamoto, T., Inagaki, N., Yano, H., Imura, H., Shigemoto, R., and Kikuchi, H. Distribution of the glucose transporters in human brain tumors. Cancer Res., 52: 3972-3979, 1992.
42. O'Rourke, J. Identification of hypoxically inducible mRNAs in HeLa. Eur. J. Biochem., 241: 403-410, 1996.
43. Airley, R. E., Loncaster, J., Raleigh, J. A., Harris, A. L., Davidson, S. E., Hunter, R. D., West, C. M., and Stratford, I. J. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding, Int. J. Cancer, 104: 85-91, 2003.
44. Bradford, B. U., Rose, M. L., Bunzendahl, H., Raleigh. J. A., Lemasters, J. J., and Thurman, R. G. Relationship of hypoxia to metallothionein expression in murine tumors. Am. J. Physiol., 276: G924-932, 1999.
45. Bussink, J., Rijken, P. F., Raleigh, J. A., Denekamp, J., Van Der Kogel, A. J., and Olive, P. L. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Int. J. Radiat. Oncol. Biol. Phys., 48: 1529-1538, 2000.